Hermetica Superfood Encyclopedia
The Short Answer
EPA (eicosapentaenoic acid) from Nannochloropsis oculata exerts cardiovascular and anti-inflammatory effects by incorporating into membrane phospholipids, modulating eicosanoid biosynthesis, and reducing hepatic triglyceride output via lipid-metabolizing enzyme pathways. In a randomized controlled trial using AlmegaPL® (250 mg EPA/day), six months of supplementation reduced serum triglycerides by 14.2% (−0.23 mmol/L, p<0.001), total cholesterol by 5.0%, and remnant cholesterol by 14.9% compared to baseline.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary KeywordEPA omega-3 Nannochloropsis oculata benefits
EPA (Omega-3) — botanical close-up
Health Benefits
**Triglyceride Reduction**
AlmegaPL®-derived EPA (250 mg/day) reduced serum triglycerides by 8.0% at 3 months and 14.2% at 6 months (p<0.001) in an RCT, supporting its role as a clinically meaningful lipid-lowering agent.
**Total and Non-HDL Cholesterol Lowering**
In the same 6-month trial, total cholesterol decreased by 5.0% (−0.26 mmol/L) and non-HDL cholesterol by 5.5% (−0.21 mmol/L), indicating a favorable shift in atherogenic lipid fractions.
**Remnant Cholesterol Reduction**: Remnant cholesterol fell by 14
9% (−0.11 mmol/L, p<0.001) at 6 months, a clinically relevant endpoint linked to residual cardiovascular risk beyond LDL cholesterol.
**Anti-Inflammatory Action**
EPA competitively displaces arachidonic acid from membrane phospholipids, reducing pro-inflammatory eicosanoid (prostaglandin E2, leukotriene B4) synthesis and modulating NF-κB signaling pathways, with preclinical evidence supporting reduced systemic inflammation.
**Enhanced Bioavailability via Polar Lipid Form**: EPA in N
oculata oil is delivered as galactolipids and phospholipids rather than triglycerides or ethyl esters, with research suggesting polar lipid vehicles improve lymphatic absorption and tissue incorporation efficiency.
**Hepatic Lipid Modulation**
Preclinical models indicate EPA from microalgal sources attenuates hepatic lipid accumulation, potentially by suppressing SREBP-1c-driven de novo lipogenesis and enhancing mitochondrial beta-oxidation of fatty acids.
**Carotenoid and Phytosterol Co-delivery**
Each AlmegaPL® capsule provides 764 µg lutein, 387 µg zeaxanthin, 541 µg beta-carotene, and 23 mg phytosterols, offering antioxidant and additional cholesterol-lowering co-benefits absent from conventional fish oil supplements.
Origin & History
Natural habitat
Nannochloropsis oculata is a unicellular marine microalga native to coastal and brackish marine environments worldwide, capable of thriving in high-salinity, high-light conditions. Commercially, it is cultivated photoautotrophically in open-pond raceway systems using brackish water and non-arable land, making it a scalable and sustainable alternative to fish- or krill-derived omega-3 sources. Unlike macroalgae or terrestrial plants, this microalga accumulates EPA (C20:5 n-3) as a primary storage fatty acid within polar membrane lipids, including galactolipids and phospholipids, at concentrations ranging from 22.2 to 37.5% of total fatty acids in optimized strains.
“Nannochloropsis oculata has no traditional medicinal use history; it is a product of modern marine biotechnology developed from the late 20th century onward as part of the global search for sustainable, fish-free omega-3 sources. Its commercial relevance emerged alongside growing scientific recognition of EPA and DHA's cardiovascular benefits in the 1980s–2000s, and concerns about overfishing and heavy metal contamination in fish-derived omega-3 supplements accelerated interest in microalgal alternatives. The development of open-pond raceway cultivation systems and metabolic engineering of algal strains (using stress-induced mutagenesis and strain selection) represents the 'traditional preparation' context for this ingredient — an industrial biotechnology process rather than an ethnobotanical one. AlmegaPL® specifically represents a first-generation commercial microalgal EPA product positioned as a vegan, sustainably sourced alternative to fish oil, reflecting broader 21st-century trends in blue biotechnology and plant-based nutrition.”Traditional Medicine
Scientific Research
The primary human evidence base for N. oculata-derived EPA consists of one published randomized controlled trial examining AlmegaPL® (providing ≥250 mg EPA/day in polar lipid form) over 6 months, which demonstrated statistically significant reductions in triglycerides, total cholesterol, non-HDL cholesterol, and remnant cholesterol (all p<0.001), though the sample size was not disclosed in available abstract-level reporting, limiting full assessment of statistical power. Preclinical studies in animal and cell models support anti-inflammatory, adipolytic, and anti-hepatic lipid accumulation effects of microalgal EPA, but these findings have not yet been confirmed in additional human trials specific to this source. The broader omega-3 EPA literature (derived from fish oil) includes hundreds of RCTs and several systematic reviews supporting cardiovascular, anti-inflammatory, and metabolic benefits, providing mechanistic plausibility; however, direct extrapolation to N. oculata polar lipid EPA should be made cautiously until source-specific human data is expanded. Overall, the evidence for this particular ingredient is promising but nascent, resting primarily on one RCT and a body of preclinical data.
Preparation & Dosage
Traditional preparation
**Polar Lipid Oil Capsule (AlmegaPL®)**
1000 mg softgel capsule daily, providing ≥250 mg EPA in galactolipid and phospholipid form; this is the only clinically studied dose for this specific ingredient
**Standardization**
23 mg), and chlorophyll (15 mg)
Commercial grade standardized to >25% w/w EPA and >15% w/w polar lipids per capsule, with co-occurring carotenoids (lutein, zeaxanthin, beta-carotene), phytosterols (.
**Extraction Method**
Ethanol extraction of whole N. oculata cells, preserving polar membrane lipids (galactolipids and phospholipids) as opposed to neutral triglycerides predominant in fish oil.
**Regulatory Status**
Registered as a New Dietary Ingredient (NDIN) in the United States, indicating reviewed safety status for dietary supplement use.
**Timing**
No specific timing guidance published for this product; general omega-3 guidance suggests taking with a fat-containing meal to optimize absorption.
**Effective Dose Range**
250 mg EPA/day (via 1000 mg AlmegaPL®) has been studied in human trials; higher doses have not been formally evaluated for this source
Only .
Nutritional Profile
Each 1000 mg AlmegaPL® capsule derived from N. oculata provides: EPA (C20:5 n-3) ≥250 mg as the primary omega-3 fatty acid; arachidonic acid (ARA, C20:4 n-6) ~40 mg; palmitoleic acid (C16:1 n-7) ~90 mg; phytosterols ~23 mg (supporting additional cholesterol modulation); chlorophyll ~15 mg; lutein ~764 µg; zeaxanthin ~387 µg; and beta-carotene ~541 µg. The fatty acid matrix is notably DHA-free, distinguishing it from fish and krill oils, and EPA is delivered primarily in polar lipid form (galactolipids and phospholipids) rather than triglycerides or ethyl esters. Bioavailability of polar lipid EPA may be superior to triglyceride-form EPA due to enhanced micellar solubility and direct phospholipid integration into intestinal cell membranes during absorption, though head-to-head bioavailability studies specific to N. oculata polar lipids versus fish oil triglycerides in humans remain limited.
How It Works
Mechanism of Action
EPA (C20:5 n-3) is incorporated into cell membrane phospholipids and galactolipids, where it competitively displaces arachidonic acid (C20:4 n-6), reducing the substrate available for cyclooxygenase (COX) and lipoxygenase (LOX) enzymes to produce pro-inflammatory prostanoids and leukotrienes, while favoring production of less inflammatory EPA-derived eicosanoids such as prostaglandin E3 and leukotriene B5. At the hepatic level, EPA activates peroxisome proliferator-activated receptor alpha (PPARα), upregulating fatty acid beta-oxidation genes and downregulating SREBP-1c-mediated triglyceride synthesis, contributing to the observed reductions in serum triglycerides and remnant cholesterol. In N. oculata mutant strains selected for enhanced EPA production, transcriptomic analysis reveals 13.7-fold upregulation of fatty acid desaturase type 2 (FAD2) and 34.8-fold upregulation of lipid droplet surface protein, indicating that EPA biosynthetic flux is channeled through enhanced desaturation of C18 precursors and optimized intracellular lipid packaging. The polar lipid delivery format (galactolipids and phospholipids) may facilitate micellar incorporation and lymphatic uptake more efficiently than triglyceride or ethyl ester forms, potentially enhancing bioavailability and downstream membrane incorporation.
Clinical Evidence
The key clinical trial investigated AlmegaPL®, a commercial polar lipid-rich EPA oil extracted from N. oculata (strain QH5), administered at 1000 mg/day (≥250 mg EPA) in participants with baseline triglycerides of 1.62 ± 0.60 mmol/L. Primary outcomes showed statistically significant triglyceride reductions of 8.0% at 3 months and 14.2% at 6 months (p<0.001), alongside secondary improvements in total cholesterol (−5.0%), non-HDL cholesterol (−5.5%), and remnant cholesterol (−14.9%) at 6 months. No adverse effects were reported over the 6-month supplementation period, suggesting reasonable tolerability at the studied dose, though the undisclosed sample size and single-trial status limit certainty. Confidence in the lipid-lowering results is moderate: effect sizes are clinically meaningful and statistically robust, but replication in larger, adequately powered, multi-center RCTs is needed before definitive conclusions can be drawn.
Safety & Interactions
In the one published 6-month RCT, AlmegaPL® at 1000 mg/day (250 mg EPA) produced no reported adverse effects, suggesting good short-term tolerability at this dose, though comprehensive long-term toxicology data specific to N. oculata polar lipid oil remains limited in the published literature. General omega-3 cautions apply: EPA at higher doses may potentiate anticoagulant and antiplatelet drugs (warfarin, clopidogrel, aspirin), theoretically increasing bleeding risk, though this interaction has not been specifically confirmed for N. oculata-derived EPA at the 250 mg/day dose. Individuals with seafood or algae allergies should exercise caution, and those with fish allergies should note this product is derived from microalgae, not fish, though cross-reactivity data is unavailable. Guidance for pregnancy and lactation has not been established for this specific product; while omega-3 fatty acids are generally considered safe and beneficial during pregnancy, the absence of DHA in this source (unlike fish oil) and limited safety data specific to this ingredient warrant physician consultation before use in these populations.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Nannochloropsis oculataEicosapentaenoic acidEPA (C20:5 n-3)AlmegaPLmicroalgal EPAomega-3 polar lipid oil
Frequently Asked Questions
What makes EPA from Nannochloropsis oculata different from fish oil EPA?
EPA from N. oculata is delivered in polar lipid forms — specifically galactolipids and phospholipids — rather than the triglyceride or ethyl ester forms found in most fish oils, which may enhance intestinal absorption and membrane incorporation. Additionally, N. oculata-derived EPA (as in AlmegaPL®) is completely DHA-free and vegan, co-delivering carotenoids (lutein, zeaxanthin, beta-carotene) and phytosterols not present in standard fish oil supplements.
How much EPA does AlmegaPL provide and what dose was used in clinical trials?
Each 1000 mg AlmegaPL® capsule provides a minimum of 250 mg EPA (≥25% w/w), along with >15% w/w polar lipids and co-occurring bioactives. The clinical trial used one 1000 mg capsule daily (250 mg EPA/day), which produced significant reductions in triglycerides, total cholesterol, and remnant cholesterol over 6 months — this is the only dose with documented human efficacy data for this specific product.
Can EPA from Nannochloropsis oculata lower triglycerides?
Yes — in a randomized controlled trial, 250 mg/day of AlmegaPL®-derived EPA reduced serum triglycerides by 8.0% (p<0.001) at 3 months and by 14.2% (−0.23 mmol/L, p<0.001) at 6 months in participants with mildly elevated baseline triglycerides of 1.62 mmol/L. Secondary lipid improvements included a 14.9% reduction in remnant cholesterol and a 5.5% reduction in non-HDL cholesterol at 6 months.
Is Nannochloropsis oculata EPA safe to take daily?
In the one published 6-month RCT, AlmegaPL® at 1000 mg/day produced no reported adverse effects, and the product holds New Dietary Ingredient (NDIN) status in the United States. However, comprehensive long-term toxicology data is limited; standard omega-3 precautions apply, including potential increased bleeding risk if combined with anticoagulants (warfarin, aspirin, clopidogrel), and those with algae allergies or who are pregnant or breastfeeding should consult a physician before use.
Is EPA from microalgae a good vegan alternative to fish oil for heart health?
N. oculata-derived EPA (e.g., AlmegaPL®) is a certified vegan, sustainable source that bypasses the fish supply chain and avoids heavy metal contamination concerns associated with some marine oils. Clinical data supports meaningful cardiovascular lipid improvements at 250 mg EPA/day, though the absence of DHA — which fish oil typically provides — means vegan users seeking both EPA and DHA may need to supplement with a separate DHA-rich algal oil for comprehensive omega-3 coverage.
Does EPA from Nannochloropsis oculata affect blood clotting or interact with blood thinners like warfarin?
EPA has mild anticoagulant properties, meaning it may have a slight blood-thinning effect at higher doses. If you are taking prescription blood thinners such as warfarin or antiplatelet medications, consult your healthcare provider before supplementing with EPA from Nannochloropsis oculata, as additive effects could theoretically increase bleeding risk. At typical supplemental doses (250 mg/day), the clinical relevance is minimal for most people, but individual risk assessment is important.
How does EPA from Nannochloropsis oculata absorption compare to other omega-3 sources, and should I take it with food?
EPA from microalgae (like Nannochloropsis oculata) is absorbed efficiently as a triglyceride form, particularly when consumed with dietary fat. Taking EPA supplements with meals containing fat enhances absorption and reduces the potential for gastrointestinal upset. The clinical trials demonstrating triglyceride and cholesterol benefits used AlmegaPL® taken with food, suggesting this is the optimal administration method.
What populations benefit most from EPA supplementation — is it primarily for people with high triglycerides?
EPA supplementation is most beneficial for individuals with elevated triglycerides, dyslipidemia, or cardiovascular risk factors; clinical evidence shows meaningful reductions in triglycerides (14.2% at 6 months) and total/non-HDL cholesterol in such populations. While vegans and vegetarians benefit from a plant-based omega-3 alternative, people with normal lipid profiles may see less dramatic clinical benefit. Those with a family history of heart disease or metabolic syndrome are also candidates for consideration under medical guidance.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w epa-eicosapentaenoic-acid-from-nannochloropsis-oculata curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
